# Tango Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2024

- Company: [Tango Therapeutics, Inc.](/companies/tngx.md) (CIK 1819133)
- Form: 10-Q
- Filed: 2024-08-07
- Accepted by EDGAR: Aug 7, 2024, 07:13 ET
- Period: 2024-06-30
- Accession: 0000950170-24-092274
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1819133/000095017024092274/tngx-20240630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1819133/000095017024092274/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-04-01 to 2024-06-30 | $19.9m | us-gaap:Revenues |
| Revenue | 6 months, 2024-01-01 to 2024-06-30 | $26.3m | us-gaap:Revenues |
| Research and development | 3 months, 2024-04-01 to 2024-06-30 | $38.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2024-01-01 to 2024-06-30 | $76.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-04-01 to 2024-06-30 | −$29.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-01-01 to 2024-06-30 | −$71.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-04-01 to 2024-06-30 | $65.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-01-01 to 2024-06-30 | $105.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-04-01 to 2024-06-30 | −$25.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-01-01 to 2024-06-30 | −$63.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.24 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.24 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-04-01 to 2024-06-30 | 108,314,279 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-01-01 to 2024-06-30 | 108,692,822 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-01-01 to 2024-06-30 | −$61.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-01-01 to 2024-06-30 | $515.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-06-30 | $51.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-06-30 | $328.4m | us-gaap:AssetsCurrent |
| Total assets | at 2024-06-30 | $381.5m | us-gaap:Assets |
| Current liabilities | at 2024-06-30 | $43.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-06-30 | $133.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-06-30 | $247.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1819133/000095017024092274/tngx-20240630.htm

Filed Aug 7, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-092274. Last ingested by Listed: Nov 4, 2026, 20:37 ET. No prices; not investment advice.